Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Alector, Inc.

ALEC Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2017โ€“FY2025

Last close ยท Oct 23, 2026

$1.83

0.0%
Compare
Revenue Total sales reported in the income statement.
$21.0M
79.1% vs prior year
Operating margin Operating income as a share of revenue.
โˆ’741.3%
597.1ย pts
Net income Profit after all expenses, interest and tax.
โˆ’$143M
Free cash flow Cash from operations minus capital spending.
โˆ’$184M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$204M
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$1.10 EPS (TTM)

What Alector, Inc. does

No business description yet.

Legal name
Alector, Inc.
Fiscal year ends
December 31, 2025
Latest annual report
10-K ยท Feb 25, 2026
Accession ยท CIK
0001193125-26-071593
0001653087

Revenue and margins

Alector, Inc. had $21.0M of revenue in fiscal 2025, down 79.1% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โˆ’$184M in fiscal 2025, โˆ’874.7% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Alector, Inc. returned โ€” to shareholders in fiscal 2025. The diluted share count rose 6.6%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Alector, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $735M$713M$549M$413M$256M
Debt incl. finance leases โ€”โ€”$0.0M$10.0M$10.4M
Debt / equity โ€”โ€”0.0x0.1x0.3x
Current ratio 5.4x7.7x3.2x3.4x3.8x
Quick ratio 5.4x7.7x3.2x3.4x3.8x
Total assets $815M$788M$622M$468M$293M
Total liabilities $514M$573M$488M$342M$263M
Shareholders' equity $301M$214M$134M$127M$30.6M
Net debt (โˆ’ = net cash) โ€”โ€”โˆ’$549Mโˆ’$403Mโˆ’$246M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Cash from operations is positive โœ• โœ“ โœ• โœ• โœ“ โœ• โœ• โœ• โœ•
Return on assets rose โ€” โ€” โœ• โœ• โœ“ โœ• โœ• โœ• โœ•
Cash from operations exceeds net income โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ• โœ• โœ•
Debt fell relative to assets โ€” โ€” โ€” โ€” โ€” โ€” โ€” โœ• โœ•
Current ratio rose โ€” โ€” โœ• โœ“ โœ• โœ“ โœ• โœ“ โœ“
Share count didn't rise โ€” โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Gross margin rose โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Revenue rose relative to assets โ€” โ€” โœ• โœ• โœ“ โœ• โœ• โœ“ โœ•
F-score โ€” / 3โ€” / 41 / 72 / 74 / 72 / 70 / 72 / 81 / 8
Accruals ratio โ€”โˆ’58.3%โˆ’1.7%โˆ’5.2%โˆ’51.4%โˆ’14.1%7.6%20.3%10.8%
Altman Z'' โ€”2.231.970.603.432.09โˆ’0.98โˆ’3.26โˆ’9.85

9 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $3.7M $27.7M $21.2M $21.1M $207M $134M $97.1M $101M $21.0M
Research and development $29.9M $73.0M $101M $157M $189M $210M $192M $186M $123M
Operating income โˆ’$32.7M โˆ’$57.3M โˆ’$114M โˆ’$195M โˆ’$37.4M โˆ’$138M โˆ’$152M โˆ’$145M โˆ’$156M
Pretax income โ€” โ€” โ€” โˆ’$190M โˆ’$36.3M โˆ’$130M โˆ’$125M โˆ’$119M โˆ’$143M
Income tax โ€” โ€” $0.0M $0.0M $0.0M $3.3M $5.2M $0.1M $0.2M
Net income โˆ’$32.5M โˆ’$52.2M โˆ’$105M โˆ’$190M โˆ’$36.3M โˆ’$133M โˆ’$130M โˆ’$119M โˆ’$143M
Diluted EPS โˆ’$3.55 โˆ’$4.62 โˆ’$1.71 โˆ’$2.45 โˆ’$0.45 โˆ’$1.62 โˆ’$1.56 โˆ’$1.23 โˆ’$1.39
Diluted shares 0.01B 0.01B 0.06B 0.08B 0.08B 0.08B 0.08B 0.10B 0.10B
Cash flow
Cash from operations โˆ’$17.8M $127M โˆ’$99.3M โˆ’$167M $299M โˆ’$20.3M โˆ’$184M โˆ’$230M โˆ’$184M
Capital expenditure $0.8M $1.9M $15.3M $5.0M $3.2M $4.1M $2.4M $1.3M $0.0M
Free cash flow โˆ’$18.6M $126M โˆ’$115M โˆ’$172M $295M โˆ’$24.4M โˆ’$187M โˆ’$231M โˆ’$184M
Depreciation and amortization $0.7M $1.0M $3.8M $5.9M $6.3M $5.7M $5.7M $5.4M $5.7M
Stock-based compensation $5.4M $6.9M $16.3M $30.5M $40.8M $46.1M $42.8M $39.5M $26.7M
Balance sheet
Cash and short-term investments $32.5M $290M $353M $413M $735M $713M $549M $413M $256M
Total debt โ€” โ€” โ€” โ€” โ€” โ€” $0.0M $10.0M $10.4M
Current assets โ€” $293M $357M $422M $750M $726M $566M $425M $266M
Current liabilities โ€” $47.9M $62.0M $68.1M $140M $93.8M $178M $125M $69.5M
Property and equipment, net โ€” $10.9M $33.9M $30.2M $27.3M $25.5M $21.9M $17.1M $10.8M
Total assets โ€” $308M $422M $488M $815M $788M $622M $468M $293M
Total liabilities โ€” $195M $227M $221M $514M $573M $488M $342M $263M
Shareholders' equity โˆ’$52.0M โˆ’$97.4M $195M $268M $301M $214M $134M $127M $30.6M
Margins
Operating margin โˆ’874.9% โˆ’207.0% โˆ’539.2% โˆ’925.1% โˆ’18.0% โˆ’103.2% โˆ’156.3% โˆ’144.2% โˆ’741.3%
EBITDA margin โˆ’856.7% โˆ’203.3% โˆ’521.4% โˆ’897.3% โˆ’15.0% โˆ’98.9% โˆ’150.4% โˆ’138.8% โˆ’714.1%
Net margin โˆ’869.6% โˆ’188.8% โˆ’496.7% โˆ’901.6% โˆ’17.5% โˆ’99.8% โˆ’134.3% โˆ’118.4% โˆ’679.2%
FCF margin โˆ’497.2% 453.7% โˆ’540.0% โˆ’814.1% 142.6% โˆ’18.3% โˆ’192.1% โˆ’229.9% โˆ’874.7%
Returns
Return on capital employed โ€” โˆ’22.0% โˆ’31.8% โˆ’46.5% โˆ’5.5% โˆ’19.9% โˆ’34.2% โˆ’42.2% โˆ’69.7%
Return on equity โ€” โ€” โˆ’216.5% โˆ’82.3% โˆ’12.8% โˆ’51.8% โˆ’74.8% โˆ’91.2% โˆ’181.6%
Return on assets โ€” โˆ’16.9% โˆ’28.9% โˆ’41.8% โˆ’5.6% โˆ’16.6% โˆ’18.5% โˆ’21.8% โˆ’37.5%
Return on tangible equity โ€” โ€” โˆ’54.1% โˆ’71.1% โˆ’12.1% โˆ’62.2% โˆ’97.2% โˆ’93.9% โˆ’466.3%
Growth
Revenue growth โ€” 641.0% โˆ’23.3% โˆ’0.6% 881.5% โˆ’35.5% โˆ’27.3% 3.6% โˆ’79.1%
FCF growth โ€” โ€” โˆ’191.2% โ€” โ€” โˆ’108.3% โ€” โ€” โ€”
Share count change โ€” 23.6% 446.2% 26.0% 3.4% 2.6% 1.5% 15.4% 6.6%
Financial health
Debt / equity โ€” โ€” โ€” โ€” โ€” โ€” 0.0x 0.1x 0.3x
Current ratio โ€” 6.1x 5.8x 6.2x 5.4x 7.7x 3.2x 3.4x 3.8x
Quick ratio โ€” 6.1x 5.8x 6.2x 5.4x 7.7x 3.2x 3.4x 3.8x
Capital allocation
Capex / revenue 21.4% 6.8% 71.9% 23.9% 1.6% 3.1% 2.5% 1.2% 0.2%
Stock comp / revenue 143.3% 25.0% 76.7% 144.7% 19.7% 34.5% 44.1% 39.2% 126.7%
Quality scores
Piotroski F-score โ€” โ€” 1.0 2.0 4.0 2.0 0.0 2.0 1.0
Altman Z'' โ€” 2.2 2.0 0.6 3.4 2.1 โˆ’1.0 โˆ’3.3 โˆ’9.9
Accruals ratio โ€” โˆ’58.3% โˆ’1.7% โˆ’5.2% โˆ’51.4% โˆ’14.1% 7.6% 20.3% 10.8%

Source: SEC EDGAR XBRL filings (CIK 0001653087). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open